Yevgeniy Feyman
It’s rare that I get to say this – but we can learn something from the United Kingdom. As our “free-market” health care system deliberates whether Gilead is charging a “just” price for its Hepatitis C (HCV) drug, Sovaldi, the UK’s National Institute for Health and Care Excellence (NICE) just approved the drug as being cost-effective, and recommended it for subgroups of patients...
The battle over Sovaldi – which costs $84,000 in the U.S. for a full course of treatment – has sparked not only outrage from insurers and pharmacy benefit managers (PBMs), but also a Senate investigation into pricing of the drug.....
Continue reading here...
Of Interest
Reducing the cost of new hepatitis C drugs
A collection of current articles addressing the high price of Gileads HCV drug Sovaldi.
No comments:
Post a Comment